Cargando…
Early 3‑day course of remdesivir for the prevention of the progression to severe COVID‑19 in the elderly: A single‑centre, real‑life cohort study
Remdesivir, a viral RNA polymerase inhibitor, has constituted a key component of therapeutic regimens against the pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Originally approved for administration in hospitalized patients, remdesivir leads to improved outcomes in...
Autores principales: | Georgakopoulou, Vasiliki Epameinondas, Gkoufa, Aikaterini, Makrodimitri, Sotiria, Basoulis, Dimitrios, Tsakanikas, Aristeidis, Karamanakos, Georgios, Mastrogianni, Elpida, Voutsinas, Pantazis M., Spandidos, Demetrios A., Papageorgiou, Chrysovalantis V., Gamaletsou, Maria N., Sipsas, Nikolaos V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469144/ https://www.ncbi.nlm.nih.gov/pubmed/37664680 http://dx.doi.org/10.3892/etm.2023.12161 |
Ejemplares similares
-
Effectiveness of Oral Nirmatrelvir/Ritonavir vs. Intravenous Three-Day Remdesivir in Preventing Progression to Severe COVID-19: A Single-Center, Prospective, Comparative, Real-Life Study
por: Basoulis, Dimitrios, et al.
Publicado: (2023) -
Characteristics and outcomes of elderly patients with Parkinson's disease hospitalized due to COVID‑19‑associated pneumonia
por: Georgakopoulou, Vasiliki Epameinondas, et al.
Publicado: (2023) -
Predictors of COVID‑19‑associated mortality among hospitalized elderly patients with dementia
por: Georgakopoulou, Vasiliki Epameinondas, et al.
Publicado: (2023) -
Factors predicting poor outcomes of patients treated with tocilizumab for COVID‑19‑associated pneumonia: A retrospective study
por: Georgakopoulou, Vasiliki Epameinondas, et al.
Publicado: (2022) -
Immature granulocytes: Innovative biomarker for SARS-CoV-2 infection
por: Georgakopoulou, Vasiliki Epameinondas, et al.
Publicado: (2022)